Aza-epothilone B

Aza-epothilone B Uses, Dosage, Side Effects, Food Interaction and all others data.

Aza-epothilone B is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Aza-epothilone B is administered through injection, and will be marketed under the trade name Ixempra. Aza-epothilone B is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation.

Table Of contents

• Aza-epothilone B
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Aza-epothilone B
Availability	Prescription only
Generic	Ixabepilone
Ixabepilone Other Names	Aza-epothilone B, Azaepothilone B, Ixabepilone
Related Drugs	Arimidex, Ibrance, Femara, Xeloda, Herceptin, Lynparza
Type
Formula	C27H42N2O5S
Weight	Average: 506.7 Monoisotopic: 506.281443634
Protein binding	67-77%
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Aza-epothilone B is a microtubule inhibitor administered in combination with capecitabine or alone in the treatment of metastatic or locally advanced breast cancer that has shown inadequate response to taxanes and anthracyclines.

Investigated for use/treatment in breast cancer, head and neck cancer, melanoma, lung cancer, lymphoma (non-hodgkin's), prostate cancer, renal cell carcinoma, and cancer/tumors (unspecified).

Aza-epothilone B is also used to associated treatment for these conditions: Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer

How Aza-epothilone B works

Binding of Aza-epothilone B to beta-tubulins (e.g. beta-III tubulin) stabilizes microtubules. Microtubules are essential to cell division, and epothilones therefore stop cells from properly dividing. Like taxol, Aza-epothilone B binds to the αβ-tubulin heterodimer subunit. Once bound, the rate of αβ-tubulin dissociation decreases, thus stabilizing the microtubules.

Food Interaction

• Avoid grapefruit products. Grapefruit inhibits the CYP3A4 metabolism of ixabepilone, which may increase its serum concentration.
• Avoid St. John's Wort. This herb induces CYP3A metabolism and may reduce serum levels of ixabepilone.

[Moderate] GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of ixabepilone.

The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.

MANAGEMENT: Patients treated with ixabepilone should avoid the consumption of grapefruit or grapefruit juice.

Aza-epothilone B Disease Interaction

Major: cytopenia, liver dysfunctionModerate: cardiovascular, neuropathy

Half Life

52 hours

Elimination Route

Mostly fecal and some renal.

Innovators Monograph

You find simplified version here Aza-epothilone B